our that PDUFA produced last factors We preparation announced receive vent resubmitted that [ph] Primatene the study that November we X, Thanks, and will PDUFA Mist we inventory have in of did we launch. then Since given date and year we remain approval for good received our from very Mist On this we NDA XXXX call, a Bill. yet. resubmission. but earnings provided a not our results date we confident our studies the a of in for Primatene human related
which the were product are confident of would of in on generic the approvals, therefore that in an approved of agency launch In that of inventory advance terms note which Based vial. version of is ampoules. on our a there the we us produce whereas us To and brand of competitive GDUFA date. Isuprel advantage allowed the happy the this to minor date. vial in Isuprel and GDUFA a FDA This announce generic is by received products the It We XXXX to product ampoule. generic advance date, XX, over other March the interesting of our this ampoule, the have FDA, our only CRL is XX product prefer July. that believe gives that approved approval receive one to days was other two typically June as vials that being was an only been is we hospitals we in XXXX, we by Isuprel
the In Isuprel of shortage many the and approval received one remains our that second FDAs XX, calcium addition in selling product chloride May it been XXXX. on unapproved the our to for for years we've on list. generic of of NDA quarter, approval This drug was we injection FDA
sodium IMS subsidiary starting manufacture of for We enoxaparin. materials also received which at supplement ANDA semi-purified at subsidiary of our USP our for our are heparin, approval manufacture FDA ANP the heparin and of the
recent targeting two our past size year, streak with file we on the $XXX Following agency now of over of have million. ANDAs market a with products approvals the over injectable
One its of quite to these patent despite complexity approved makes generic time. and ANDAs some for due never majority had up being a the the XXX has of million our
We next inspection year our We have remain year. on first file X be whether to still on for and the needed. depending facility first ANDA injectable file two GDUFA dates this in plan to of target will XXXX this ANDAs half in to inhalation more product X
FDA now is have beneficial ways our changing France, franchise diabetes up year the subsidiary to approved Amphastar as has XX expected as environment grow Nanjing active in for insulin Pharmaceuticals. ingredients on. business materials ANP our including three insulin facility look currently has APIs in we market. ramping Amphastar products products, API eight APIs the expansion and and these our starting and finished may China. we but ANP DMFs file spending sell R&D bring generic and on In and recently to products. as announced goes plans starting for date, to July, To parties begin our progress approved use AFP has to four our projects ANP great in APIs increase in our FDA on regulatory to Our additional Isuprel provided facility is pharmaceutical for we will to from both materials with The DMFs. revenues. making the its third be the to is developing only ANP
completed assets ANP is sell generic of expansion approximately a global begin million. pharmaceutical retained and With prefilled us of of existing for that in equity ANP. regard and XX% product ANP help to equity product interest believe vial More Depo-Provera We and on most raising to other up expansion, scale selling expect our the has ANP to To our distribution to his ANP products recent globally. private of leverage $XX importantly, the to in both launches, effective in finished ramp markets way for fund the a this XXXX. and china syringe. we continue the our externally products expanding is Amphastar in approximately manufacture placement
this share market we we on that the call, last year. As by be achieved quarter strong third that reflected more believe have stated we of a should the fully and
to Our strong a just given vial other vial month launched achieve market Finally, was one approved hopeful last market.\ is share in generic FDA Neostigmine With over that only begin Isuprel product the I call there we although to achieved. and turn to that we update, now is are happy operator the penetration more that have competitive, with the market Q&A. the we will the are
